** Traws Pharma's TRAW.O shares soar 129% to $11.30 premarket
** TRAW says its experimental bird flu drug, tivoxavir marboxil, was safe and well-tolerated in early-stage trial
** A single dose maintained levels of the drug in the blood for over 23 days in the trial, co says
** Mid-stage trial is expected to begin in H1 2025, co says
** Bird flu has infected more than 860 dairy herds in 16 U.S. states since March and killed 123 million poultry since the outbreak began in 2022
** As of last close, stock has fallen 73.2% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。